Cost of revenues:
Laboratory services (47,096) (22,656)
Manufacturing services (34,445) (10,460)
Total cost of revenues (81,541) (33,116)
Gross Profit 46,356 30,946 50%
Operating expenses:
Selling and marketing expenses (3,359) (1,215) 176%
General and administrative expenses (23,610) (16,384) 44%
Total operating expenses (26,969) (17,599) 53%
Operating income 19,387 13,347 45%
Other income (expenses), net:
Other income (expenses), net 527 851
Interest income (expenses), net 495 (745)
Total other income (expenses), net 1,022 106
Income before income taxes 20,409 13,453 52%
Income taxes 1,972 (329)
Net income 22,381 13,124 71%
Amount attributed to:
Deemed dividend on issuance and
repurchase of preference shares -- (7,612)
Amounts allocated to preference shares
for participating rights to dividends -- (2,856)
Income attributable to holders of ADS
(Note 2):
Basic 22,381 2,656
Diluted 22,381 2,656
Basic earnings per ADS (Note 2) 0.36 0.11
Diluted earnings per ADS (Note 2) 0.31 0.09
Weighted average ADS outstanding -
basic (Note 2) 62,241,856 23,873,225
Weighted average ADS outstanding -
diluted (Note 2)
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved |